Skip to main content
Top
Published in: Journal of Gastroenterology 3/2013

01-03-2013 | Original Article—Liver, Pancreas, and Biliary Tract

The impact of patatin-like phospholipase domain-containing protein 3 polymorphism on hepatocellular carcinoma prognosis

Authors: Yasuto Takeuchi, Fusao Ikeda, Yuki Moritou, Hiroaki Hagihara, Tetsuya Yasunaka, Kenji Kuwaki, Yasuhiro Miyake, Hideki Ohnishi, Shinichiro Nakamura, Hidenori Shiraha, Akinobu Takaki, Yoshiaki Iwasaki, Kazuhiro Nouso, Kazuhide Yamamoto

Published in: Journal of Gastroenterology | Issue 3/2013

Login to get access

Abstract

Background

The single nucleotide polymorphism (SNP) rs738409 in patatin-like phospholipase domain-containing protein 3 (PNPLA3) is associated with hepatic fat accumulation and disease progression in patients with non-alcoholic fatty liver disease and alcoholic liver disease (ALD). This study was conducted to determine whether PNPLA3 rs738409 SNPs affect development and prognosis of hepatocellular carcinoma (HCC) in patients with various liver diseases.

Methods

We enrolled 638 consecutive Japanese patients newly diagnosed with HCC between 2001 and 2010: 72 patients with hepatitis B virus (HBV), 462 with hepatitis C virus (HCV), and 104 with non-B non-C (NBNC).

Results

NBNC patients exhibited large tumors of advanced TNM stages at HCC diagnosis, and had significantly poorer prognosis than HBV or HCV patients (P < 0.001 and <0.001, respectively; log-rank test). The G/G genotype of PNPLA3 rs738409 SNP had significantly higher distribution in NBNC patients (P < 0.001) and was significantly associated with higher body mass index (BMI) and an increased aspartate aminotransferase to platelet ratio index. No significant differences were observed in survival with differences in PNPLA3 SNP genotypes among the patients, although ALD patients with the G/G genotype of PNPLA3 SNP and low BMI had significantly poorer survival than those with high BMI (P = 0.028).

Conclusions

The G/G genotype of PNPLA3 rs738409 SNP was more frequently distributed, and associated with BMI and fibrosis among NBNC-HCC patients but not among HBV or HCV patients. These genotypes might affect HCC prognosis in ALD patients, but not in HBV, HCV, or NAFLD patients.
Literature
1.
go back to reference El-Serag HB, Marrero JA, Reddy KR, et al. Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology. 2008;134:1752–63.PubMedCrossRef El-Serag HB, Marrero JA, Reddy KR, et al. Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology. 2008;134:1752–63.PubMedCrossRef
2.
go back to reference Kawaguchi T, Taniguchi E, Sata M, et al. The pathogenesis, complications and therapeutic strategy for hepatitis C virus-associated insulin resistance in the era of anti-viral treatment. Rev Recent Clin Trials. 2010;5:147–57.PubMedCrossRef Kawaguchi T, Taniguchi E, Sata M, et al. The pathogenesis, complications and therapeutic strategy for hepatitis C virus-associated insulin resistance in the era of anti-viral treatment. Rev Recent Clin Trials. 2010;5:147–57.PubMedCrossRef
3.
go back to reference Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology. 2010;51:1820–32.PubMedCrossRef Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology. 2010;51:1820–32.PubMedCrossRef
4.
go back to reference Fattovich G, Stroffolini T, Donato F, et al. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology. 2004;127:S35–50.PubMedCrossRef Fattovich G, Stroffolini T, Donato F, et al. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology. 2004;127:S35–50.PubMedCrossRef
5.
go back to reference Hassan MM, Hwang LY, Patt YZ, et al. Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus. Hepatology. 2002;36:1206–13.PubMedCrossRef Hassan MM, Hwang LY, Patt YZ, et al. Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus. Hepatology. 2002;36:1206–13.PubMedCrossRef
6.
go back to reference Kiyosawa K, Umemura T, Tanaka E, et al. Hepatocellular carcinoma: recent trends in Japan. Gastroenterology. 2004;127:S17–26.PubMedCrossRef Kiyosawa K, Umemura T, Tanaka E, et al. Hepatocellular carcinoma: recent trends in Japan. Gastroenterology. 2004;127:S17–26.PubMedCrossRef
7.
go back to reference Taura N, Fukushima N, Taketomi A, et al. The incidence of hepatocellular carcinoma associated with hepatitis C infection decreased in Kyushu area. Med Sci Monit. 2010;17:PH7–11. Taura N, Fukushima N, Taketomi A, et al. The incidence of hepatocellular carcinoma associated with hepatitis C infection decreased in Kyushu area. Med Sci Monit. 2010;17:PH7–11.
8.
go back to reference Abe H, Yoshizawa K, Aizawa Y, et al. Etiology of non-B non-C hepatocellular carcinoma in the eastern district of Tokyo. J Gastroenterol. 2008;43:967–74.PubMedCrossRef Abe H, Yoshizawa K, Aizawa Y, et al. Etiology of non-B non-C hepatocellular carcinoma in the eastern district of Tokyo. J Gastroenterol. 2008;43:967–74.PubMedCrossRef
9.
go back to reference Marchesini G, Bugianesi E, Rizzetto M, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology. 2003;37:917–23.PubMedCrossRef Marchesini G, Bugianesi E, Rizzetto M, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology. 2003;37:917–23.PubMedCrossRef
10.
12.
go back to reference Hui JM, Kench JG, George J, et al. Long-term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C. Hepatology. 2003;38:420–7.PubMedCrossRef Hui JM, Kench JG, George J, et al. Long-term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C. Hepatology. 2003;38:420–7.PubMedCrossRef
13.
go back to reference Sugimoto K, Takei Y. Clinicopathological features of non-alcoholic fatty liver disease. Hepatol Res. 2011;41:911–20.PubMedCrossRef Sugimoto K, Takei Y. Clinicopathological features of non-alcoholic fatty liver disease. Hepatol Res. 2011;41:911–20.PubMedCrossRef
14.
go back to reference Nouso K, Kobayashi Y, Yamamoto K, et al. Evolution of prognostic factors in hepatocellular carcinoma in Japan. Aliment Pharmacol Ther. 2010;31:407–14.PubMedCrossRef Nouso K, Kobayashi Y, Yamamoto K, et al. Evolution of prognostic factors in hepatocellular carcinoma in Japan. Aliment Pharmacol Ther. 2010;31:407–14.PubMedCrossRef
15.
go back to reference Bosch FX, Ribes J, Diaz M, Cleries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology. 2004;127:S5–6.PubMedCrossRef Bosch FX, Ribes J, Diaz M, Cleries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology. 2004;127:S5–6.PubMedCrossRef
16.
go back to reference Falleti E, Fabris C, Pirisi M, et al. Interleukin-6 polymorphisms and gender: relationship with the occurrence of hepatocellular carcinoma in patients with end-stage liver disease. Oncology. 2009;77:304–13.PubMedCrossRef Falleti E, Fabris C, Pirisi M, et al. Interleukin-6 polymorphisms and gender: relationship with the occurrence of hepatocellular carcinoma in patients with end-stage liver disease. Oncology. 2009;77:304–13.PubMedCrossRef
17.
go back to reference Yang Y, Luo C, Feng R, Bi S. The TNF-alpha, IL-1B and IL-10 polymorphisms and risk for hepatocellular carcinoma: a meta-analysis. J Cancer Res Clin Oncol. 2010. doi:10.1007/s00432-010-0959-8. Yang Y, Luo C, Feng R, Bi S. The TNF-alpha, IL-1B and IL-10 polymorphisms and risk for hepatocellular carcinoma: a meta-analysis. J Cancer Res Clin Oncol. 2010. doi:10.​1007/​s00432-010-0959-8.
18.
go back to reference Wilson PA, Gardner SD, Crowther DJ, et al. Characterization of the human patatin-like phospholipase family. J Lipid Res. 2006;47:1940–9.PubMedCrossRef Wilson PA, Gardner SD, Crowther DJ, et al. Characterization of the human patatin-like phospholipase family. J Lipid Res. 2006;47:1940–9.PubMedCrossRef
19.
go back to reference Huang Y, He S, Hobbs HH, et al. A feed-forward loop amplifies nutritional regulation of PNPLA3. Proc Natl Acad Sci USA. 2010;107:7892–7.PubMedCrossRef Huang Y, He S, Hobbs HH, et al. A feed-forward loop amplifies nutritional regulation of PNPLA3. Proc Natl Acad Sci USA. 2010;107:7892–7.PubMedCrossRef
20.
go back to reference Kershaw EE, Hamm JK, Flier JS, et al. Adipose triglyceride lipase: function, regulation by insulin, and comparison with adiponutrin. Diabetes. 2006;55:148–57.PubMedCrossRef Kershaw EE, Hamm JK, Flier JS, et al. Adipose triglyceride lipase: function, regulation by insulin, and comparison with adiponutrin. Diabetes. 2006;55:148–57.PubMedCrossRef
21.
go back to reference Romeo S, Kozlitina J, Hobbs HH, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet. 2008;40:1461–5.PubMedCrossRef Romeo S, Kozlitina J, Hobbs HH, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet. 2008;40:1461–5.PubMedCrossRef
22.
go back to reference Rotman Y, Koh C, Liang TJ, et al. The association of genetic variability in patatin-like phospholipase domain-containing protein 3 (PNPLA3) with histological severity of nonalcoholic fatty liver disease. Hepatology. 2010;52:894–903.PubMedCrossRef Rotman Y, Koh C, Liang TJ, et al. The association of genetic variability in patatin-like phospholipase domain-containing protein 3 (PNPLA3) with histological severity of nonalcoholic fatty liver disease. Hepatology. 2010;52:894–903.PubMedCrossRef
23.
go back to reference Valenti L, Al-Serri A, Day CP, et al. Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease. Hepatology. 2010;51:1209–17.PubMedCrossRef Valenti L, Al-Serri A, Day CP, et al. Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease. Hepatology. 2010;51:1209–17.PubMedCrossRef
24.
go back to reference Tian C, Stokowski RP, Hinds DA, et al. Variant in PNPLA3 is associated with alcoholic liver disease. Nat Genet. 2010;42:21–3.PubMedCrossRef Tian C, Stokowski RP, Hinds DA, et al. Variant in PNPLA3 is associated with alcoholic liver disease. Nat Genet. 2010;42:21–3.PubMedCrossRef
25.
go back to reference Kudo M, Okanoue T. Management of hepatocellular carcinoma in Japan: consensus-based clinical practice manual proposed by the Japan Society of Hepatology. Oncology. 2007;72(Suppl 1):2–15.PubMedCrossRef Kudo M, Okanoue T. Management of hepatocellular carcinoma in Japan: consensus-based clinical practice manual proposed by the Japan Society of Hepatology. Oncology. 2007;72(Suppl 1):2–15.PubMedCrossRef
26.
go back to reference Makuuchi M, Kokudo N, Arii S. Clinical practice guidelines for hepatocellular carcinoma—the Japan Society of Hepatology 2009 update. Hepatol Res. 2010;40(Suppl 1):2–144. Makuuchi M, Kokudo N, Arii S. Clinical practice guidelines for hepatocellular carcinoma—the Japan Society of Hepatology 2009 update. Hepatol Res. 2010;40(Suppl 1):2–144.
27.
go back to reference Liver Cancer Study Group of Japan. The general rules for the clinical and pathological study of primary liver cancer. 5th ed. Tokyo: Kanehara; 2009. p. 19 (in Japanese). Liver Cancer Study Group of Japan. The general rules for the clinical and pathological study of primary liver cancer. 5th ed. Tokyo: Kanehara; 2009. p. 19 (in Japanese).
28.
go back to reference Valenti L, Al-Serri A, Day CP, et al. Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease. Hepatology. 2010;51:1209–17.PubMedCrossRef Valenti L, Al-Serri A, Day CP, et al. Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease. Hepatology. 2010;51:1209–17.PubMedCrossRef
29.
go back to reference Kollerits B, Coassin S, Kronenberg F, et al. A common variant in the adiponutrin gene influences liver enzyme values. J Med Genet. 2010;47:116–9.PubMedCrossRef Kollerits B, Coassin S, Kronenberg F, et al. A common variant in the adiponutrin gene influences liver enzyme values. J Med Genet. 2010;47:116–9.PubMedCrossRef
30.
go back to reference Kotronen A, Johansson LE, Yki-Järvinen H, et al. A common variant in PNPLA3, which encodes adiponutrin, is associated with liver fat content in humans. Diabetologia. 2009;52:1056–60.PubMedCrossRef Kotronen A, Johansson LE, Yki-Järvinen H, et al. A common variant in PNPLA3, which encodes adiponutrin, is associated with liver fat content in humans. Diabetologia. 2009;52:1056–60.PubMedCrossRef
31.
go back to reference Kotronen A, Peltonen M, Yki-Järvinen H, et al. Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors. Gastroenterology. 2009;137:865–72.PubMedCrossRef Kotronen A, Peltonen M, Yki-Järvinen H, et al. Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors. Gastroenterology. 2009;137:865–72.PubMedCrossRef
32.
go back to reference Kantartzis K, Peter A, Stefan N, et al. Dissociation between fatty liver and insulin resistance in humans carrying a variant of the patatin-like phospholipase 3 gene. Diabetes. 2009;58:2616–23.PubMedCrossRef Kantartzis K, Peter A, Stefan N, et al. Dissociation between fatty liver and insulin resistance in humans carrying a variant of the patatin-like phospholipase 3 gene. Diabetes. 2009;58:2616–23.PubMedCrossRef
33.
go back to reference Sookoian S, Castaño GO, Pirola CJ, et al. A nonsynonymous gene variant in the adiponutrin gene is associated with nonalcoholic fatty liver disease severity. J Lipid Res. 2009;50:2111–6.PubMedCrossRef Sookoian S, Castaño GO, Pirola CJ, et al. A nonsynonymous gene variant in the adiponutrin gene is associated with nonalcoholic fatty liver disease severity. J Lipid Res. 2009;50:2111–6.PubMedCrossRef
34.
go back to reference Speliotes EK, Butler JL, Hirschhorn JN, et al. PNPLA3 variants specifically confer increased risk for histologic nonalcoholic fatty liver disease but not metabolic disease. Hepatology. 2010;52:904–12.PubMedCrossRef Speliotes EK, Butler JL, Hirschhorn JN, et al. PNPLA3 variants specifically confer increased risk for histologic nonalcoholic fatty liver disease but not metabolic disease. Hepatology. 2010;52:904–12.PubMedCrossRef
35.
go back to reference Kawaguchi T, Sumida Y, Matsuda F, et al. Genetic polymorphisms of the human PNPLA3 gene are strongly associated with severity of non-alcoholic fatty liver disease in Japanese. PLoS One. 2012;7:e38322.PubMedCrossRef Kawaguchi T, Sumida Y, Matsuda F, et al. Genetic polymorphisms of the human PNPLA3 gene are strongly associated with severity of non-alcoholic fatty liver disease in Japanese. PLoS One. 2012;7:e38322.PubMedCrossRef
36.
go back to reference Inoue M, Iwasaki M, Tsugane S, et al. Diabetes mellitus and the risk of cancer: results from a large-scale population-based cohort study in Japan. Arch Intern Med. 2006;166:1871–7.PubMedCrossRef Inoue M, Iwasaki M, Tsugane S, et al. Diabetes mellitus and the risk of cancer: results from a large-scale population-based cohort study in Japan. Arch Intern Med. 2006;166:1871–7.PubMedCrossRef
37.
go back to reference Hara M, Sasaki S. Japan Public Health Center Study Group. Effect of smoking on the association between alcohol consumption and cancer mortality among middle-aged Japanese men: JPHC Study Cohort I. IARC Sci Publ. 2002;156:165–8.PubMed Hara M, Sasaki S. Japan Public Health Center Study Group. Effect of smoking on the association between alcohol consumption and cancer mortality among middle-aged Japanese men: JPHC Study Cohort I. IARC Sci Publ. 2002;156:165–8.PubMed
38.
go back to reference Ishiguro S, Inoue M, Tsugane S, JPHC Study Group, et al. Serum aminotransferase level and the risk of hepatocellular carcinoma: a population-based cohort study in Japan. Eur J Cancer Prevent. 2009;18:26–32.CrossRef Ishiguro S, Inoue M, Tsugane S, JPHC Study Group, et al. Serum aminotransferase level and the risk of hepatocellular carcinoma: a population-based cohort study in Japan. Eur J Cancer Prevent. 2009;18:26–32.CrossRef
Metadata
Title
The impact of patatin-like phospholipase domain-containing protein 3 polymorphism on hepatocellular carcinoma prognosis
Authors
Yasuto Takeuchi
Fusao Ikeda
Yuki Moritou
Hiroaki Hagihara
Tetsuya Yasunaka
Kenji Kuwaki
Yasuhiro Miyake
Hideki Ohnishi
Shinichiro Nakamura
Hidenori Shiraha
Akinobu Takaki
Yoshiaki Iwasaki
Kazuhiro Nouso
Kazuhide Yamamoto
Publication date
01-03-2013
Publisher
Springer Japan
Published in
Journal of Gastroenterology / Issue 3/2013
Print ISSN: 0944-1174
Electronic ISSN: 1435-5922
DOI
https://doi.org/10.1007/s00535-012-0647-3

Other articles of this Issue 3/2013

Journal of Gastroenterology 3/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.